TICKERNERD
Menu
CNSYCNSYHealthcare · Biotechnology

CNSY Stock Forecast: Cerenome, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$3.03
+0.83% on the day

The 4 Wall Street analysts covering Cerenome, Inc. hold a median 12-month price target of $38 — +1139.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 19 of 100 as at 21 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$20.7M
Ticker Nerd rank
19 / 100
Median analyst target
$38
Analysts covering
4
Total return, dividends reinvested
1W
−17.8%
1M
−22.8%
YTD
−76.3%
1Y
−74.8%
From 52W high
−86.4%
From 52W low
+3.6%
$3
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CNSY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cerenome, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
19 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
88
Accruals
53
Growth
43
Revisions
40
Value
30
Quality
29
Volatility
23
Issuance
18
Momentum
7

Size (88): Smaller than most of the companies we track.

Momentum (7): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CNSY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNSY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26CNSYHigh $57Median $38Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $12Median $38High $57

The green dot is the last close — the median target sits +1139.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 June 2026Ascendiant CapitalMaintainsBuy$65 → $57
8 June 2026Ascendiant CapitalMaintainsBuy—
9 Apr 2026Ascendiant CapitalMaintainsBuy—
31 Mar 2026D. Boral CapitalDowngradeHold—
19 Mar 2026D. Boral CapitalMaintainsBuy—
23 Jan 2026HC Wainwright & Co.MaintainsBuy—
22 Jan 2026D. Boral CapitalMaintainsBuy—
8 Jan 2026D. Boral CapitalMaintainsBuy—
11 Dec 2025D. Boral CapitalMaintainsBuy—
1 Dec 2025D. Boral CapitalMaintainsBuy—
21 Nov 2025Ascendiant CapitalMaintainsBuy—
20 Nov 2025D. Boral CapitalMaintainsBuy—
3 Nov 2025HC Wainwright & Co.MaintainsBuy—
31 Oct 2025D. Boral CapitalMaintainsBuy—
21 Oct 2025D. Boral CapitalMaintainsBuy—
6 Oct 2025Ascendiant CapitalMaintainsBuy—
25 Sept 2025D. Boral CapitalMaintainsBuy—
22 Sept 2025D. Boral CapitalMaintainsBuy—
18 Sept 2025D. Boral CapitalMaintainsBuy—
3 Sept 2025D. Boral CapitalUpgradeBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CNSY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CNSY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Cerenome, Inc. (CNSY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.1×

Cheaper than 71% of US stocks

Price / sales
4.4×

Cheaper than 29% of US stocks

Price / book
4.2×

Cheaper than 26% of US stocks

EV / EBITDA
−0.6×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
−2.9%

Higher than 23% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−692.5%

Higher than 7% of US stocks

Net margin
−230.2%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−560.2%

Higher than 3% of US stocks

Return on assets
−73.8%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CNSY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CNSYCerenome, Inc.$20.7M
19
MRKRMarker Therapeutics, Inc.$23.2M
59
ALLRAllarity Therapeutics, Inc.$22.8M
30
JSPRJasper Therapeutics, Inc.$23.8M
38
CELUCelularity, Inc.$22.7M
18
ABVCABVC BioPharma, Inc.$22.6M
14
CLRBCellectar Biosciences, Inc.$24.5M
25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cerenome, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CNSY news & analysis

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

GlobeNewsWire · 20 Aug 2026positive

Cerenome highlighted presentations at the 2026 SNO/ASCO CNS Metastases Conference demonstrating progress in both its therapeutics and diagnostics business lines. The data showed REYOBIQ CSF distribution and safety, and CNSide's potential to reduce monthly leptomeningeal treatment costs by up to 47%.

Why it matters — A CNSY watcher would care because the presentations signal advancement across both the therapeutics and diagnostics businesses, including safety data for REYOBIQ and potential cost savings for CNSide.

Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 14 Aug 2026negative

Cerenome (CNSY) reported a second-quarter loss of $1.31 per share, wider than the Zacks Consensus Estimate of a $0.96 per-share loss and larger than the $0.25 per-share loss a year earlier, resulting in a miss on revenue estimates.

Why it matters — CNSY watchers would note that the company's quarterly loss came in significantly worse than both analyst expectations and the prior-year period, reflecting deteriorating quarterly performance.

Cerenome Launches as an Integrated CNS Oncology Company

GlobeNewsWire · 31 July 2026neutral

Plus Therapeutics, Inc. announced that its corporate rebrand to Cerenome will be completed as scheduled, with the name change to Cerenome, Inc. effective August 3, 2026. The company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol "CNSY" at market open that day.

Why it matters — PSTV shareholders should note that the stock will trade under a new ticker symbol (CNSY) and the company will operate under a new name (Cerenome, Inc.) starting August 3, 2026.

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

GlobeNewsWire · 28 July 2026positive

Plus Therapeutics announced that two posters highlighting its ReSPECT-LM clinical development program and CNSide diagnostic platform will be presented at the 2026 SNO/ASCO CNS Metastases Conference, and that the Company and its subsidiary will host a sponsored symposium on redefining the management of leptomeningeal metastases.

Why it matters — A PSTV watcher would care because the presentations and symposium raise the company's visibility in the CNS cancer field and showcase its clinical and diagnostic pipeline at a major industry conference.

FAQ

Frequently asked questions about CNSY stock

What is the CNSY stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Cerenome, Inc. have a median 12-month price target of $38, with estimates ranging from $12 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CNSY stock a buy right now?

Of the 4 analysts covering Cerenome, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cerenome, Inc. 19 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CNSY?

As at 21 Aug 2026, Cerenome, Inc. ranks 19 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).

Will CNSY stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +1139.7% from the last close, and Ticker Nerd's factor model ranks Cerenome, Inc. 19 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CNSY stock forecast for 2030?

No analyst covering Cerenome, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNSY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $57 over the next 12 months.

How has CNSY stock performed over the past year?

Cerenome, Inc. returned -74.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cerenome, Inc. do?

Cerenome, Inc. is a central nervous system oncology company focused on improving detection and treatment of cancers affecting the brain and spinal cord.

What is the latest news on CNSY?

The most recent item we track (GlobeNewsWire, 20 Aug 2026): "Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines". Cerenome highlighted presentations at the 2026 SNO/ASCO CNS Metastases Conference demonstrating progress in both its therapeutics and diagnostics business lines. The data showed REYOBIQ CSF distribution and safety, and CNSide's potential to reduce monthly leptomeningeal treatment costs by up to 47%.

Company

About Cerenome, Inc.

Cerenome, Inc. is a central nervous system oncology company focused on improving detection and treatment of cancers affecting the brain and spinal cord. The company operates an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence-driven data analytics to address complex CNS malignancies. Its activities span the development and commercialization of radiotherapeutic drugs for rare and difficult-to-treat cancers, including recurrent glioblastoma and other CNS tumors, as well as solid organ cancers such as primary and secondary liver cancers. Cerenome also offers specialized laboratory-developed tests, notably the CNSide assay, designed to identify tumor cells that have metastasized to the central nervous system in patients with systemic cancers. By linking advanced diagnostics with innovative therapeutic modalities, Cerenome plays a distinct role in the healthcare and biotechnology sectors, targeting areas of high unmet medical need in oncology. The company is headquartered in Houston, Texas and operates today as a clinical-stage enterprise serving providers and patients involved in CNS cancer care.

CEO Dr. Marc H. Hedrick M.B.A., M.D. · 28 employees · United States · https://cerenome.com